SYHX2011
Phase 3Small molecule
SYHX2011 is one of 71 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
2
Indications
4
Total Trials
2
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1SYHX2011
CCSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3
Zolymbus
AbbViePreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Acupan
YYonsei University
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SYHX2011. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details